Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 5/2014

01-05-2014 | Research Article

Association between X-ray repair cross-complementing group 1 Arg194Trp polymorphism and prostate cancer risk

Authors: Feng He, Guizhong Li, Libo Man, Ning Liu

Published in: Tumor Biology | Issue 5/2014

Login to get access

Abstract

X-ray repair cross-complementing group 1 (XRCC1) plays an important role in the maintenance of the genomic integrity. Previous studies on the association between XRCC1 Arg194Trp polymorphism and prostate cancer risk reported conflicting results. To get a more precise assessment of the association between XRCC1 Arg194Trp polymorphism and prostate cancer risk, we performed a meta-analysis of previously published studies. Eligible studies were searched in PubMed, Embase, and China National Knowledge Infrastructure (CNKI) databases. Nine studies with a total of 5,407 subjects were finally included into the meta-analysis. Odds ratio (OR) with 95 % confidence interval (95 %CI) was used to assess the association. Overall, there was no obvious association between XRCC1 Arg194Trp polymorphism and prostate cancer risk (Trp vs. Arg: OR = 1.02, 95 %CI 0.84–1.25, P = 0.824; TrpTrp vs. ArgArg: OR = 1.17, 95 %CI 0.83–1.66, P = 0.374; TrpTrp/ArgTrp vs. ArgArg: OR = 1.00, 95 %CI 0.79–1.28, P = 0.990; TrpTrp vs. ArgArg/ArgTrp: OR = 1.20, 95 %CI 0.85–1.68, P = 0.301). Subgroup analysis according to ethnicity also detected no significant association in both Asians and Caucasians. In conclusion, the meta-analysis suggests that there is no obvious association between XRCC1 Arg194Trp polymorphism and prostate cancer risk.
Literature
1.
2.
Pienta KJ, Smith DC. Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin. 2005;55:300–18. quiz 23-5.CrossRefPubMed
3.
Kasper JS, Liu Y, Giovannucci E. Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer. 2009;124:1398–403.CrossRefPubMedPubMedCentral
4.
McCracken M, Olsen M, Chen Jr MS, Jemal A, Thun M, Cokkinides V, et al. Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J Clin. 2007;57:190–205.CrossRefPubMed
5.
6.
Shiloh Y, Ziv Y. The atm protein kinase: regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol. 2013;14:197–210.CrossRef
7.
Schipler A, Iliakis G. DNA double-strand-break complexity levels and their possible contributions to the probability for error-prone processing and repair pathway choice. Nucleic Acids Res. 2013;41:7589–605.CrossRefPubMedPubMedCentral
8.
Goodarzi AA, Jeggo PA. The repair and signaling responses to DNA double-strand breaks. Adv Genet. 2013;82:1–45.PubMed
9.
Horton JK, Watson M, Stefanick DF, Shaughnessy DT, Taylor JA, Wilson SH. Xrcc1 and DNA polymerase beta in cellular protection against cytotoxic DNA single-strand breaks. Cell Res. 2008;18:48–63.CrossRefPubMedPubMedCentral
10.
Caldecott KW. Xrcc1 and DNA strand break repair. DNA Repair (Amst). 2003;2:955–69.CrossRef
11.
Harms C, Salama SA, Sierra-Torres CH, Cajas-Salazar N, Au WW. Polymorphisms in DNA repair genes, chromosome aberrations, and lung cancer. Environ Mol Mutagen. 2004;44:74–82.CrossRefPubMed
12.
Bartsch H, Dally H, Popanda O, Risch A, Schmezer P. Genetic risk profiles for cancer susceptibility and therapy response. Recent Results Cancer Res. 2007;174:19–36.CrossRefPubMed
13.
Xu Z, Hua LX, Qian LX, Yang J, Wang XR, Zhang W, et al. Relationship between xrcc1 polymorphisms and susceptibility to prostate cancer in men from Han, Southern China. Asian J Androl. 2007;9:331–8.CrossRefPubMed
14.
Hamano T, Matsui H, Ohtake N, Nakata S, Suzuki K. Polymorphisms of DNA repair genes, xrcc1 and xrcc3, and susceptibility to familial prostate cancer in a Japanese population. Asia Pac J Clin Oncol. 2008;4:21–6.CrossRef
15.
Gao R, Price DK, Dahut WL, Reed E, Figg WD. Genetic polymorphisms in xrcc1 associated with radiation therapy in prostate cancer. Cancer Biol Ther. 2010;10:13–8.CrossRefPubMedPubMedCentral
16.
Agalliu I, Kwon EM, Salinas CA, Koopmeiners JS, Ostrander EA, Stanford JL. Genetic variation in DNA repair genes and prostate cancer risk: results from a population-based study. Cancer Causes Control. 2010;21:289–300.CrossRefPubMed
17.
van Gils CH, Bostick RM, Stern MC, Taylor JA. Differences in base excision repair capacity may modulate the effect of dietary antioxidant intake on prostate cancer risk: an example of polymorphisms in the xrcc1 gene. Cancer Epidemiol Biomarkers Prev. 2002;11:1279–84.PubMed
18.
Mandal RK, Gangwar R, Mandhani A, Mittal RD. DNA repair gene X-ray repair cross-complementing group 1 and xeroderma pigmentosum group d polymorphisms and risk of prostate cancer: a study from north India. DNA Cell Biol. 2010;29:183–90.CrossRefPubMed
19.
Hirata H, Hinoda Y, Tanaka Y, Okayama N, Suehiro Y, Kawamoto K, et al. Polymorphisms of DNA repair genes are risk factors for prostate cancer. Eur J Cancer. 2007;43:231–7.CrossRefPubMed
20.
Mittal RD, Mandal RK, Gangwar R. Base excision repair pathway genes polymorphism in prostate and bladder cancer risk in north Indian population. Mech Ageing Dev. 2012;133:127–32.CrossRefPubMed
21.
22.
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed
23.
24.
Ginsberg G, Angle K, Guyton K, Sonawane B. Polymorphism in the DNA repair enzyme xrcc1: utility of current database and implications for human health risk assessment. Mutat Res. 2011;727:1–15.CrossRefPubMed
25.
Liu F, Li B, Wei Y, Yan L, Wen T, Zhao J, et al. Xrcc1 genetic polymorphism arg399gln and hepatocellular carcinoma risk: a meta-analysis. Liver Int. 2011;31:802–9.CrossRefPubMed
26.
Karahalil B, Bohr VA, Wilson 3rd DM. Impact of DNA polymorphisms in key DNA base excision repair proteins on cancer risk. Hum Exp Toxicol. 2012;31:981–1005.CrossRefPubMedPubMedCentral
Metadata
Title
Association between X-ray repair cross-complementing group 1 Arg194Trp polymorphism and prostate cancer risk
Authors
Feng He
Guizhong Li
Libo Man
Ning Liu
Publication date
01-05-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1528-y

Other articles of this Issue 5/2014

Tumor Biology 5/2014 Go to the issue

Research Article

Microsatellite instability and promoter hypermethylation in colorectal cancer in India

Research Article

Kallikrein-related peptidase-6 (KLK6) mRNA expression is an independent prognostic tissue biomarker of poor disease-free and overall survival in colorectal adenocarcinoma

Research Article

Hypoxia and hypoxia-inducible factor 1 repress SEMA4B expression to promote non-small cell lung cancer invasion

Research Article

The Glu298Asp polymorphism in the NOS3 gene and the risk of prostate cancer

Research Article

The impact of arsenic trioxide and all-trans retinoic acid on p53 R273H-codon mutant glioblastoma

Review

MicroRNA-21 is a novel promising target in cancer radiation therapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits